The Trump administration’s pick for Assistant Secretary for Preparedness and Response has a history of linking hepatitis B …
The Trump administration’s pick for Assistant Secretary for Preparedness and Response has a history of linking hepatitis B …
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
The supplemental approval for exagamglogene autotemcel gives families of children with recurrent vaso-occlusive crises a one-time gene-editing option …
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention …
Recent clinical developments offer hope for immunosuppression-free diabetes treatment while raising serious questions about safety in gene therapy …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Inclusion in major indexes highlights aTyr’s expanding biotech footprint and investor recognition amid advancing therapeutic pipeline.
Already a subscriber? Log in